Product Code: GDHC030CL
GlobalData's "Schizophrenia - Competitive Landscape in 2020" combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
5-hydroxytryptamine (5-HT) and dopamine receptors are the major focus of drug developers. There are 143 drugs in the pipeline, 39 of which targets 5-HT or dopamine receptors. Big pharma dominates R&D in this indication, with Otsuka, Johnson & Johnson, Lundbeck, and Roche leading the way. Increasing incidence expected to drive growth in schizophrenia market. The increasing awareness and approval of late-stage pipeline molecules will drive the market's growth over the coming years, but lack of curative treatment and increasing generic penetration will limit the growth.
This reports provides a data-driven overview of the current and future competitive landscape in schizophrenia therapeutics.
Scope
Components of the report include -
- Disease epidemiology
- Marketed drugs assessment
- Pipeline drugs assessment
- Clinical trials assessment
- Commercial assessment
- Social media overview
- Digital marketing overview
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global schizophrenia market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global schizophrenia market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
1.Table of Contents
- 1.1 Preface
- 1.2 Abbreviations
- 1.3 Related Reports
- 1.4 Upcoming Related Reports
2 Executive Summary
- 2.1 Key Findings
- 2.2 Key Events
3 Introduction
- 3.1 Report Scope
- 3.2 Disease Overview Epidemiology Overview
- 3.3 Epidemiology
4 Marketed Drugs Assessment
- 4.1 Marketed Drugs Overview
- 4.2 Marketed Drug Profiles
5 Pipeline Assessment
- 5.1 Pipeline Overview
- 5.2 Pipeline Breakdown by Region
- 5.3 Pipeline Breakdown by Molecule Type and Target
- 5.4 Drug Review Designations
- 5.5 Phase Transition Success Rates
- 5.6 Likelihood of Approval
6 Clinical Trial Assessment
- 6.1 Clinical Trials Overview by Phase
- 6.2 Overview by Region
- 6.4 Therapy Area Perspective
- 6.4 Leading Sponsors
- 6.5 Enrollment Analytics
- 6.6 Feasibility Analysis
7 Commercial Assessment
- 7.1 Upcoming Market Catalysts
8 Social Media and Digital Marketing
- 8.1 Key Twitter Chatter
- 8.2 Top Branded Websites
- 8.3 Trust Flow and Citation Flow
9 Appendix
- 9.1 Methodology
- 9.2 About the Authors
- 9.3 About GlobalData
- 9.4 Contact Us
- 9.5 Disclaimer
